Palvella Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Palvella Therapeutics, Inc. carries a market capitalization of 1.85B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.85B |
| Enterprise Value | 1.95B |
Share Statistics
Palvella Therapeutics, Inc. currently has 14.40M shares outstanding.
| Shares Outstanding | 14.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 10.14 |
| P/TBV Ratio | 10.14 |
| P/FCF Ratio | -53.72 |
| P/OCF Ratio | -53.72 |
Financial Position
Palvella Therapeutics, Inc. maintains a current ratio of 21.18, meaning it holds 21.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.25, indicating conservative leverage, while an interest coverage ratio of -7.60 demonstrates limited ability to service its debt obligations.
| Current Ratio | 21.18 |
| Quick Ratio | 20.97 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -7.60 |
Financial Efficiency
| Return on Equity (ROE) | -46.63 |
| Return on Assets (ROA) | -37.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Palvella Therapeutics, Inc.'s stock has gained approximately 65.53367% over the past 52 weeks. The 50-day moving average sits at 144.76, while the 200-day moving average is 125.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | 65.53367% |
| 50-Day Moving Average | 144.76 |
| 200-Day Moving Average | 125.30 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -57.74M, while operating income came in at -57.74M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -57.74M |
| Pretax Income | -61.70M |
| Net Income | -61.70M |
| EBITDA | -57.74M |
| EBIT | -57.74M |
| Earnings Per Share (EPS) | -4.81 |
Balance Sheet
Palvella Therapeutics, Inc. holds 250.58M in cash and equivalents against 535,000.00 in total debt, resulting in a net debt position of -187.80M. Total book value stands at 216.87M, with working capital of 241.08M providing operational flexibility.
| Cash & Cash Equivalents | 250.58M |
| Total Debt | 535,000.00 |
| Net Debt | -187.80M |
| Equity (Book Value) | 216.87M |
| Book Value Per Share | 15.06 |
| Working Capital | 241.08M |
Cash Flow
Palvella Therapeutics, Inc. produced -36.51M in operating cash flow over the past twelve months.
| Operating Cash Flow | -36.51M |
| Capital Expenditures | N/A |
| Free Cash Flow | -36.51M |
| FCF Per Share | -2.84 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.83 |
| FCF Yield | -1.86 |
Stock Splits
Palvella Therapeutics, Inc.'s most recent stock split took place on April 23, 2024 with a 80:1 split ratio.
| Last Split Date | 4/23/2024 |
| Split Ratio | 80:1 |
Scores
Palvella Therapeutics, Inc. posts an Altman Z-Score of 35.46, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 35.46 |